Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Reply from Kahlmeter and Giske to Brecher, ‘EUCAST and CLSI Point-Counterpoint on Susceptibility Breakpoints: Do Two “I Agree”s Miss the Point?’

Gunnar Kahlmeter, Christian G. Giske
Alexander J. McAdam, Editor
Gunnar Kahlmeter
aDepartment of Clinical Microbiology, Växjö Central Hospital, Växjö, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian G. Giske
bDepartment of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
cDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander J. McAdam
Boston Children’s Hospital
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.01519-19
  • Article
  • Info & Metrics
  • PDF
Loading

REPLY

Stephen M. Brecher argues that the world at large would benefit from a merge between the systems created separately by EUCAST and CLSI. This would probably be applauded by most international colleagues, provided the merged committee were industry neutral and noncommercial, with a transparent decision process, and with breakpoint tables and other documents available free of charge. Moreover, it would be desirable if the committee had a public consultation process where all countries could have a voice, all decisions were taken in a timely manner, and where all agents available in the world would have breakpoints and methods assigned to them.

In 2001, six of seven countries (France, Germany, Norway, Sweden, The Netherlands, and the United Kingdom) decided to convert national breakpoint committees to scientific bodies of reference and to feed into a joint committee, EUCAST. Since then, EUCAST has rapidly grown in popularity and is now used not only in Europe, but in countries on all continents. EUCAST has a formal role in the determination of breakpoints for new and existing agents. CLSI has retained its status as a national committee although with international advisors. However, the influence of U.S. federal law is prominent, and breakpoints in the United States are determined not only by CLSI, but also by the FDA.

EUCAST and CLSI consult each other regularly and over the years ran joint working groups. Most certainly, all will agree that we influence each other’s work and decisions. Thus far, such joint initiatives had to be financed one by one, separately by each party, and identifying funding has frequently been challenging. Moreover, the two committees lack a common decision process, our financing is different, and the timelines for decisions are different. The financing of EUCAST is public, and the output, including background data, is in its entirety freely available on the EUCAST website. We are still a long way from a merge, and it is unclear from where the initiative should come. The urge and money to drive such a committee have not been forthcoming, and it would entail a long and challenging process.

FOOTNOTES

  • This is a response to a letter by Brecher (https://doi.org/10.1128/JCM.01444-19).

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

PreviousNext
Back to top
Download PDF
Citation Tools
Reply from Kahlmeter and Giske to Brecher, ‘EUCAST and CLSI Point-Counterpoint on Susceptibility Breakpoints: Do Two “I Agree”s Miss the Point?’
Gunnar Kahlmeter, Christian G. Giske
Journal of Clinical Microbiology Dec 2019, 58 (1) e01519-19; DOI: 10.1128/JCM.01519-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Reply from Kahlmeter and Giske to Brecher, ‘EUCAST and CLSI Point-Counterpoint on Susceptibility Breakpoints: Do Two “I Agree”s Miss the Point?’
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Reply from Kahlmeter and Giske to Brecher, ‘EUCAST and CLSI Point-Counterpoint on Susceptibility Breakpoints: Do Two “I Agree”s Miss the Point?’
Gunnar Kahlmeter, Christian G. Giske
Journal of Clinical Microbiology Dec 2019, 58 (1) e01519-19; DOI: 10.1128/JCM.01519-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • REPLY
    • FOOTNOTES
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X